Salivary $LDOC1$ is a gender-difference biomarker of oral squamous cell carcinoma

Chung-Ji Liu$^{1,2,3,4,*}$, Jen-Hao Chen$^{5,6,*}$, Shih-Min Hsia$^7$, Chiu-Chu Liao$^8$, Hui-Wen Chang$^8$, Tzong-Ming Shieh$^9$ and Yin-Hwa Shih$^8$

$^1$ Department of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, Taipei, Taiwan
$^2$ Mackay Medical College, Taipei, Taiwan
$^3$ Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
$^4$ Institute of Oral Biology, School of Dentistry, National Yang-Ming University, Taipei, Taiwan
$^5$ School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
$^6$ Prosthodontics Department, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
$^7$ School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei, Taiwan
$^8$ Department of Healthcare Administration, Asia University, Taichung, Taiwan
$^9$ Department of Dental Hygiene, College of Health Care, China Medical University, Taichung, Taiwan

$^*$ These authors contributed equally to this work.

ABSTRACT

**Background.** The X-linked tumor suppressor gene $LDOC1$ is reported to be involved in oral cancer. The detection of biomarkers in salivary RNA is a non-invasive strategy for diagnosing many diseases. The aim of the present study was to investigate the potential of salivary $LDOC1$ as a biomarker of oral cancer.

**Methods.** We determined the expression levels of $LDOC1$ in the saliva of oral squamous cell carcinoma (OSCC) subjects, and investigated its correlation with various clinico-pathological characteristics. The expression levels of salivary $LDOC1$ were detected in 53 OSCC subjects and 43 healthy controls using quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis. We used Fisher’s exact test to analyze the correlations between expression levels and clinico-pathological characteristics.

**Results.** Salivary $LDOC1$ was significantly upregulated in females with OSCC ($p = 0.0072$), and significantly downregulated in males with OSCC ($p = 0.0206$). Eighty-nine percent of male OSCC subjects who smoked expressed low levels of $LDOC1$. OSCC cell lines derived from male OSCC subjects expressed low levels of $LDOC1$.

**Conclusions.** A high level of salivary $LDOC1$ expression is a biomarker of OSCC in females. A high percentage of male OSCC subjects who smoke express low levels of salivary $LDOC1$. A low level of salivary $LDOC1$ expression is a biomarker of OSCC in males.

INTRODUCTION

Oral cancer, which is a common malignancy with worldwide distribution, is two or three times more prevalent in males than in females (Rivera, 2015). The primary currently known lifestyle-related risk factors include smoking, drinking, and betel chewing, which
are reportedly more common in males than in females (Muscat et al., 1996). There is evidence that males are exposed to more risk factors than women, which explains the higher incidence of oral cancer in males (Amtha et al., 2014; Chatterjee, Gupta & Bose, 2015). Oral squamous cell carcinoma (OSCC) accounts for more than 90% of oral cancers cases (Kao & Lim, 2015; Markopoulos, 2012). The late TNM stages are associated with poor 5-year survival rates. Therefore, early diagnosis and treatment are important with regard to oral cancer.

The diagnosis of oral cancer always performed by the dentists with visual examination and palpation of the oral mucosa (Shibahara, 2017). Saliva contains abundant RNA molecules (Fabryova & Celec, 2014; Li et al., 2006), which serve as potential diagnostic markers of cancer (Achour & Aguilo, 2018; Chen et al., 2018; Chi et al., 2018; Thiele et al., 2018; Yu et al., 2017). Moreover, saliva collection is a non-invasive method that can be used to detect risk-associated biomarkers for diseases, and is more acceptable to certain age groups—i.e., children and the elderly—than blood sampling (Liu & Duan, 2012; Zhang et al., 2016). There has been a surge of recent studies investigated in the potential use of salivary biomarkers to detect oral cancer (Sinevici & O’Sullivan, 2016). However, there are few studies of salivary X-link gene as biomarkers of oral cancer.

The Knudson’s two-hit mechanism describes the loss of function of tumor suppressor genes in both autosomal chromosome alleles. However, the loss of X-linked tumor suppressor gene function challenges the “two-hit inactivation” theory. A single genetic hit is sufficient to cause tumor development and prognosis. The aberrant expression of tumor suppressor genes on the X chromosome contributes to ovarian cancer (Yang-Feng et al., 1992), breast cancer (Sirchia et al., 2005), and prostate cancer (Stephan et al., 2002), and affects individuals that are more susceptible to cancer formation (Spatz, Borg & Feunteun, 2004).

Leucine Zipper, Down-regulated in Cancer-1 (LDOC1) is an X-linked tumor suppressor gene. It plays a crucial role in modulating cell proliferation via the NFκB signaling pathway (Thoompumkal et al., 2016). The hypermethylation of the LDOC1 promoter region and the downregulation of LDOC1 in ovarian and cervical cancer cell lines (Buchholtz et al., 2014; Buchholtz et al., 2013) increase cell proliferation. Low LDOC1 expression levels have been correlated with oral cancer caused by exposure to cigarette smoke (Lee et al., 2015). However, some studies have reported that LDOC1 overexpression increases cell proliferation and is correlated with poor prognosis (Duzkale et al., 2011; Song et al., 2013). There have been few investigations into the effect of LDOC1 expression in oral cancer. The role of LDOC1 in oral cancer formation requires further clarification.

In the present study, we determined salivary LDOC1 expression levels in oral squamous cell carcinoma (OSCC) subjects to investigate the potential of salivary LDOC1 as a biomarker of oral cancer.

**MATERIALS & METHODS**

Clinical samples
The present study was approved by the Institutional Review Board (IRB) of MacKay Memorial Hospital (IRB number 17MMHIS053). Salivary samples from 53 OSCC patients
and 43 normal subjects were kindly provided by the Department of Medical Research of MacKay Memorial Hospital. The saliva samples were collected from the OSCC subjects before surgery, and all samples were collected by spitting. The samples were immediately placed in DNase- and RNase-free tubes, and centrifuged at 2,000 g and 4 °C for 10 min to remove the cellular fraction. The supernatants were stored at −80 °C until required.

**Salivary RNA extraction**

The salivary RNA was extracted from each sample using a PureLink RNA Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) to produce a 200 µL solution containing the RNA. We reduced the volume of these solutions to 10 µL each by ethanol precipitation. The RNA samples were then dissolved in nuclease-free water and stored at −80 °C until required.

**Quantitative reverse transcription polymerase chain reaction (qRT-PCR)**

We used a random primer to reverse transcribe the RNA, as described in our previous study (Yin-Hua Shih et al., 2015). The design of the primers used for the two genes used in the qRT-PCR experiment (LDOC1 and GAPDH) were taken from the Roche Universal ProbeLibrary website. The qRT-PCR was performed using a Roche LC-480 instrument (Roche, Basel, Switzerland), and the PCR regimen comprised: denaturing at 95 °C for 10 min, annealing at 60 °C for 30 s, extension at 72 °C for 1 s, and a total run of 60 cycles. The fold change in gene expression was compared between the OSCC and normal groups. The threshold of the statistical table was twofold higher or twofold lower than the average fold change in the normal group.

**Statistical analysis**

We carried out the statistical analyses using Prism version 5 (GraphPad Software, San Diego, CA, USA) and SPSS version 12 (IBM Corporation, Quezon, Philippines). The data are expressed as the mean ± SD. Group differences were analyzed using the Mann–Whitney U test and Fisher’s exact test. A p-value of <0.05 was taken to indicate statistical significance.

**RESULTS**

**Clinicopathological characteristics of the 53 OSCC subjects**

We enrolled 53 OSCC subjects and 43 normal subjects in the present study. Of the OSCC subjects: 20 were under 55 years old (37.7%) and 33 were over 55 (62.3%); the average age was 56.6; 27 were male and 26 were female; and 25 subjects smoked (47.1%) and 28 (52.9%) did not. The clinical characteristics are listed in Table 1; they include other factors such as drinking, betel chewing, tumor size, tumor differentiation, clinical stage, node metastasis, recurrence, radiotherapy, and tumor site. Two subjects experienced tumor recurrence and two subjects experienced node metastasis.

**LDOC1 expression in the OSCC subjects differed between the genders**

The saliva samples were collected from the OSCC subjects by the Oral Maxillofacial Surgery Department doctors before the oral cancer operations. The saliva was immediately treated
| Feature               | N(%)            |
|----------------------|-----------------|
| **Age, y**           |                 |
| <55                  | 20 (37.7)       |
| ≥55                  | 33 (62.3)       |
| **Sex**              |                 |
| Male                 | 27 (50.9)       |
| Female               | 26 (49.1)       |
| **Smoke**            |                 |
| Yes                  | 25 (47.1)       |
| No                   | 28 (52.9)       |
| **Drink**            |                 |
| Yes                  | 16 (30.1)       |
| No                   | 37 (69.9)       |
| **Betal chewing**    |                 |
| Yes                  | 21 (40.7)       |
| No                   | 32 (59.3)       |
| **Tumor size**       |                 |
| T1-T2                | 27 (50.9)       |
| T3-T4                | 26 (49.1)       |
| **Differentiation**  |                 |
| Well                 | 26 (49)         |
| Moderate             | 22 (41.5)       |
| Poor                 | 5 (9.5)         |
| **Clinical stage**   |                 |
| I–II                 | 20 (37.7)       |
| III–IV               | 33 (62.3)       |
| **Node metastasis**  |                 |
| Yes                  | 2 (3.7)         |
| No                   | 51 (96.3)       |
| **Recurrence**       |                 |
| Yes                  | 2 (3.7)         |
| No                   | 51 (96.3)       |
| **Radiotherapy**     |                 |
| Yes                  | 20 (37.7)       |
| No                   | 33 (62.3)       |
| **Tumor site**       |                 |
| Buccal               | 14 (26.4)       |
| Tongue               | 19 (35.8)       |
| Others               | 20 (37.8)       |
Figure 1  The salivary LDOC1 expression in OSCC subjects and normal subjects. (A) The comparison of all subjects including female and male. (B) The comparison of female subjects. (C) The comparison of male subjects; males with OSCC N = 27, females with OSCC N = 26, normal male N = 16, normal female N = 27; Mann–Whitney U test.

prior to storage according to the proper procedure mentioned above in the Materials & Methods section. We extracted the total RNA from the saliva and reverse transcribed it into complementary DNA (cDNA) using a random primer. The LDOC1 cycle threshold (Ct) value was determined by the qRT-PCR machine. We compared the LDOC1 expression levels between all the OSCC subjects and normal subjects, and found no significant differences (Fig. 1A). The subjects were then separated by gender and the LDOC1 expression levels were compared. The LDOC1 expression levels were significantly higher in females with OSCC ($p = 0.0072$) and significantly lower in males with OSCC ($p = 0.0206$). Figure 1 reveals significant differences in LDOC1 expression levels between male and female OSCC subjects compared to those in normal subjects. The LDOC1 expression levels showed gender-difference in the OSCC subjects.

A high proportion of male OSCC subjects smoked and had low LDOC1 expression levels

We statistically analyzed the correlations between LDOC1 expression levels and various clinicopathological characteristics. There was no significant correlation between the clinicopathological characteristics and LDOC1 expression levels in either the male or female OSCC subjects (Tables 2 and 3). However, among the 27 males with OSCC, the LDOC1 expression levels were low in 24 (88.8%) cases, of whom more than 60% had a history of smoking (79.1%), a history of betel chewing (66.6%), had well-differentiated tumors (66.6%), were in clinical stages III–IV (65.4%), had no recurrence (83.3%), and no node metastasis (100%).

The OSCC cell line derived from male OSCC subjects exhibited low LDOC1 expression

We determined the levels of LDOC1 expression in OSCC cell lines derived from OSCC subjects. Three of the cell lines derived from males with OSCC (HSC3, Cal27, and OECM-1), and one cell line derived from females with OSCC (SAS) had no LDOC1 amplicons in the electrophoresis gel. We added a lung carcinoma cell line (A549) and a gingival cell line (SG), which were derived from male subjects, for comparison (Fig. 2). The low LDOC1 expression levels in all the male OSCC cell lines provide secondary evidence that low LDOC1 expression is correlated with male gender in OSCC.
Table 2  The correlation between salivary LDOC1 expression and clinicopathological characteristics in females with OSCC.

| Feature               | LDOC1 expression | P value |
|-----------------------|------------------|---------|
|                       | >2 fold N        | Others N|
| **Age, y**            |                  |         |
| <55                   | 3                | 6       | 1       |
| ≥55                   | 6                | 11      |         |
| **Smoke**             |                  |         |
| Yes                   | 2                | 1       | 0.27    |
| No                    | 7                | 16      |         |
| **Drink**             |                  |         |
| Yes                   | 1                | 0       | 0.35    |
| No                    | 8                | 17      |         |
| **Betal chewing**     |                  |         |
| Yes                   | 3                | 1       | 0.1     |
| No                    | 6                | 16      |         |
| **Tumor size**        |                  |         |
| T1–T2                 | 4                | 11      | 0.42    |
| T3–T4                 | 5                | 6       |         |
| **Differentiation**   |                  |         |
| Well                  | 4                | 4       | 0.37    |
| Moderate              | 5                | 10      |         |
| Poor                  | 0                | 3       |         |
| **Clinical stage**    |                  |         |
| I–II                  | 3                | 8       | 0.68    |
| III–IV                | 6                | 9       |         |
| **Node metastasis**   |                  |         |
| Yes                   | 0                | 1       | 1       |
| No                    | 9                | 16      |         |
| **Recurrence**        |                  |         |
| Yes                   | 0                | 0       | 1       |
| No                    | 9                | 17      |         |
| **Radiotherapy**      |                  |         |
| Yes                   | 3                | 5       | 1       |
| No                    | 6                | 12      |         |
| **Tumor site**        |                  |         |
| Buccal                | 3                | 1       | 0.12    |
| Tongue                | 3                | 11      |         |
| Others (Gingiva, palate) | 3 | 5 | |

**Notes.**
Fisher’s exact test, two tail; N, subject number; the definition of LDOC1 expression threshold described in ‘Materials and Methods’.
Table 3. The correlation between salivary LDOC1 expression and clinicopathological characteristics in males with OSCC.

| Feature                  | LDOC1 expression | P value |
|--------------------------|------------------|---------|
|                          | <2 fold N (%)    | Others N |
| Age, y                   |                  |         |
| <55                      | 13 (54.1)        | 1       | 0.5956 |
| ≥55                      | 11 (45.9)        | 2       |        |
| Smoke                    |                  |         |
| Yes                      | 19 (79.1)        | 3       | 1      |
| No                       | 5 (20.9)         | 0       |        |
| Drink                    |                  |         |
| Yes                      | 12 (50)          | 3       | 0.2308 |
| No                       | 12 (50)          | 0       |        |
| Betel chewing            |                  |         |
| Yes                      | 16 (66.6)        | 1       | 0.535  |
| No                       | 8 (33.4)         | 2       |        |
| Tumor size               |                  |         |
| T1–T2                    | 10 (46.1)        | 2       | 0.5692 |
| T3–T4                    | 14 (53.9)        | 1       |        |
| Differentiation          |                  |         |
| Well                     | 16 (66.6)        | 2       | 1      |
| Moderate                 | 6 (25)           | 1       |        |
| Poor                     | 2 (8.4)          | 0       |        |
| Clinical stage           |                  |         |
| I–II                     | 8 (33.4)         | 1       | 1      |
| III–IV                   | 16 (66.6)        | 2       |        |
| Node metastasis          |                  |         |
| Yes                      | 0 (0)            | 1       | 0.1111 |
| No                       | 24 (100)         | 2       |        |
| Recurrence               |                  |         |
| Yes                      | 2 (16.7)         | 0       | 1      |
| No                       | 22 (83.3)        | 3       |        |
| Radiotherapy             |                  |         |
| Yes                      | 12 (50)          | 0       | 0.2308 |
| No                       | 12 (50)          | 3       |        |
| Tumor site               |                  |         |
| Buccal                   | 9 (37.5)         | 1       | 1      |
| Tongue                   | 4 (16.6)         | 0       |        |
| Others (gingiva, palate, mouth floor) | 11 (45.9) | 2 |        |

Notes. Fisher's exact test, two tail; N, subject number; the definition of the LDOC1 expression threshold described in 'Materials and Methods'.
**DISCUSSION**

Numerous studies have provided evidence to support the use of aberrant expression levels of tumor suppressor genes as a biomarker for the diagnosis of OSCC. To the best of our knowledge, the present study is the first investigation of the use of the expression levels of an X-linked gene in the saliva of OSCC subjects as a biomarker.

When it comes to enrollment of subjects, and collection of saliva. Males are two or three times more susceptible to oral cancer than females. Therefore, most clinical studies of oral cancer involve more male than female subjects. We aimed to investigate the relationship between the aberrant expression of an X-linked tumor suppressor gene and oral cancer. We deliberately attempted to enroll equal percentages of male and female OSCC subjects. As Table 1 shows, the final ratio of males to females was 1.2:1. Saliva collection in the present study was limited because it is difficult to collect saliva from patients suffering from severe oral cancer, especially those who have received both chemotherapy and radiotherapy and suffer from a dry mouth symptom. Therefore, most of the saliva specimens were collected from subjects without recurrence (96.3%) or node metastasis (96.3%).

Our qRT-PCR data revealed no significant difference between all the OSCC subjects and all the normal subjects (Fig. 1A). When we analyzed the \textit{LDOC1} expression levels by gender, we found that there was a significant difference between male and female OSCC subjects compared to normal males and females (Figs. 1B and 1C). The literatures provided evidence of both upregulation and downregulation of \textit{LDOC1} resulting in cancer. For future work, an \textit{in vivo} investigation into how the difference in \textit{LDOC1} expression levels between the genders contributes to the various mechanisms underlying tumorigenesis is required.

Several cancer studies have reported hypermethylation in the \textit{LDOC1} promoter region \cite{Buchholtz14, Buchholtz13, Lee15}, and that \textit{LDOC1} silencing is associated with a history of cigarette smoking \cite{Lee13}. In our data, smoking was more prevalent in the males than in the females (12% in the females with OSCC and 88% in the males with OSCC). However, smoking was not significantly associated with \textit{LDOC1} expression in males with OSCC (Table 3). The association between \textit{LDOC1} expression and smoking in OSCC remains unclear and is a potential future research topic.

We determined the \textit{LDOC1} expression levels in OSCC cell lines derived from male and female OSCC subjects (Fig. 2). We have no information regarding the smoking habits of...
the OSCC subjects who donated the cells, but there was no evidence of LDOC1 amplicon expression on the electrophoresis gel in any of the OSCC cell lines (three derived from males and one derived from females). This suggests that an absence of LDOC1 expression in oral cells may be one of the causes of tumorigenesis.

CONCLUSIONS

In summary, salivary LDOC1 is a gender-difference biomarker of OSCC. Whether aberrant LDOC1 expression contributes to OSCC is still unclear owing to a lack of direct evidence. Future in vitro and in vivo studies are required to determine how gender-specific LDOC1 expression contributes to oral cancer.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This research was funded by the following grants from the Ministry of Science and Technology, Taiwan (MOST 107-2314-B-468-007, MOST 106-2314-B-037-012, MOST 106-2314-B-039-003-MY2 and NSC 102-2314-B-039-015-MY) and from a grant from the Kaohsiung Medical University Hospital (KMUH106-6M55). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Ministry of Science and Technology, Taiwan: MOST 107-2314-B-468-007, MOST 106-2314-B-037-012, MOST 106-2314-B-039-003-MY2, NSC 102-2314-B-039-015-MY. Kaohsiung Medical University Hospital: KMUH106-6M55.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
- Chung-Ji Liu prepared figures and/or tables, authored or reviewed drafts of the paper, subjects enrollment.
- Jen-Hao Chen prepared figures and/or tables, authored or reviewed drafts of the paper, offering the funding.
- Shih-Min Hsia and Tzong-Ming Shieh contributed reagents/materials/analysis tools.
- Chiu-Chu Liao and Hui-Wen Chang performed the experiments, analyzed the data.
- Yin-Hwa Shih conceived and designed the experiments, analyzed the data, approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
The study was approved by the IRB of MacKay Memorial Hospital (No. 17MMHIS053).
Data Availability
The following information was supplied regarding data availability:

The raw data of clinicopathological characteristics and the Ct value of LDOC1 are
available in the Supplemental Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.6732#supplemental-information.

REFERENCES

Achour C, Aguilo F. 2018. Long non-coding RNA and Polycomb: an intricate partnership in cancer biology. Frontiers in Bioscience 23:2106–2132 DOI 10.2741/4693.

Amtha R, Razak IA, Basuki B, Roeslan BO, Gautama W, Puwanto DJ, Ghani WM, Zain RB. 2014. Tobacco (karet) smoking, betel quid chewing and risk of oral cancer in a selected Jakarta population. Asian Pacific Journal of Cancer Prevention 15:8673–8678 DOI 10.7314/APJCP.2014.15.20.8673.

Buchholtz ML, Bruning A, Mylonas I, Juckstock J. 2014. Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells. Archives of Gynecology and Obstetrics 290:149–154 DOI 10.1007/s00404-014-3177-9.

Buchholtz ML, Juckstock J, Weber E, Mylonas I, Dian D, Bruning A. 2013. Loss of LDOC1 expression by promoter methylation in cervical cancer cells. Cancer Investigation 31:571–577 DOI 10.3109/07357907.2013.845671.

Chatterjee R, Gupta B, Bose S. 2015. Oral screening for pre-cancerous lesions among areca-nut chewing population from rural India. Oral Health and Preventive Dentistry 13:509–514 DOI 10.3290/j.ohpd.a34052.

Chen L, Zhang YH, Pan X, Liu M, Wang S, Huang T, Cai YD. 2018. Tissue expression difference between mRNAs and lncRNAs. International Journal of Molecular Sciences 19(11):3416 DOI 10.3390/ijms19113416.

Chi H, Yang R, Zheng X, Zhang L, Jiang R, Chen J. 2018. LncRNA RP11-79H23.3 functions as a competing endogenous RNA to regulate PTEN expression through sponging hsa-miR-107 in the development of bladder cancer. International Journal of Molecular Sciences 19(9):2531 DOI 10.3390/ijms19092531.

Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O’Brien S, Wierda WG, Pfleger J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV. 2011. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood 117(15):4076–4084 DOI 10.1182/blood-2010-09-304881.

Fabryova H, Celec P. 2014. On the origin and diagnostic use of salivary RNA. Oral Dis 20:146–152 DOI 10.1111/odi.12098.

Kao SY, Lim E. 2015. An overview of detection and screening of oral cancer in Taiwan. Chinese Journal of Dental Research 18:7–12.
Lee CH, Pan KL, Tang YC, Tsai MH, Cheng AJ, Shen MY, Cheng YM, Huang TT, Lin P. 2015. LDOC1 silenced by cigarette exposure and involved in oral neoplastic transformation. Oncotarget 6:25188–25201 DOI 10.18632/oncotarget.4512.

Lee CH, Wong TS, Chan JY, Lu SC, Lin P, Cheng AJ, Chen YJ, Chang JS, Hsiao SH, Leu YW, Li CI, Hsiao JR, Chang JY. 2013. Epigenetic regulation of the X-linked tumour suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. Journal of Pathology 230:298–309 DOI 10.1002/path.4173.

Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, Abemayor E, Wong DT. 2006. Serum circulating human mRNA profiling and its utility for oral cancer detection. Journal of Clinical Oncology 24:1754–1760 DOI 10.1200/JCO.2005.03.7598.

Liu J, Duan Y. 2012. Saliva: a potential media for disease diagnostics and monitoring. Oral Oncology 48:569–577 DOI 10.1016/j.oraloncology.2012.01.021.

Markopoulos AK. 2012. Current aspects on oral squamous cell carcinoma. The Open Dentistry Journal 6:126–130 DOI 10.2174/1874210601206010126.

Muscat JE, Richie Jr JP, Thompson S, Wynder EL. 1996. Gender differences in smoking and risk for oral cancer. Cancer Research 56:5192–5197.

Rivera C. 2015. Essentials of oral cancer. International Journal of Clinical and Experimental Pathology 8:11884–11894.

Shibahara T. 2017. Oral cancer -diagnosis and therapy-. Clinical Calcium 27(10):1427–1433.

Sinevici N, O’Sullivan J. 2016. Oral cancer: deregulated molecular events and their use as biomarkers. Oral Oncology 61:12–18 DOI 10.1016/j.oraloncology.2016.07.013.

Sirchia SM, Ramoscelli L, Grati FR, Barbera F, Coradini D, Rossella F, Porta G, Lesma E, Ruggeri A, Radice P, Simoni G, Miozzo M. 2005. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Cancer Research 65:2139–2146 DOI 10.1158/0008-5472.CAN-04-3465.

Song Z, Dong R, Zhao R, Zheng S. 2013. Overexpression of LDOC1 in human biliary epithelial cells inhibits apoptosis through NF-κB signaling. Journal of Pediatric Gastroenterology and Nutrition 57(6):713–717 DOI 10.1097/MPG.0b013e3182a7e1da.

Spatz A, Borg C, Feunteun J. 2004. X-chromosome genetics and human cancer. Nature Reviews Cancer 4:617–629 DOI 10.1038/nrc1413.

Stephan DA, Howell GR, Teslovich TM, Coffey AJ, Smith L, Bailey-Wilson JE, Malechek L, Gildea D, Smith JR, Gillanders EM, Schleutker J, Hu P, Steingruber HE, Dhami P, Robbins CM, Makalowska I, Carpten JD, Sood R, Mumm S, Reinbold R, Bonner TJ, Baffoe-Bonnie A, Bubendorf L, Heiskanen M, Kallioneimi OP, Baxevanis AD, Joseph SS, Zucchi I, Burk RD, Isaacs W, Ross MT, Trent JM. 2002. Physical and transcript map of the hereditary prostate cancer region at xq27. Genomics 79:41–50 DOI 10.1006/geno.2001.6681.

Thiele JA, Hosek P, Kralovcova E, Ostasov P, Liska V, Bruha J, Vyczital O, Rosendorf J, Opattova A, Horak J, Kraklickova M, Vodicka P, Pitule P. 2018. IncRNAs in non-malignant tissue have prognostic value in colorectal cancer. International Journal of Molecular Sciences 19(9):2672 DOI 10.3390/ijms19092672.
Thoompumkal IJ, Rehna K, Anbarasu K, Mahalingam S. 2016. Leucine zipper down-regulated in cancer-1 (LDOC1) interacts with Guanine nucleotide binding protein-like 3-like (GNL3L) to modulate nuclear factor-kappa B (NF-kappaB) signaling during cell proliferation. *Cell Cycle* 15:3251–3267 DOI 10.1080/15384101.2016.1242534.

Yang-Feng TL, Li S, Han H, Schwartz PE. 1992. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. *International Journal of Cancer* 52:575–580 DOI 10.1002/ijc.2910520414.

Yin-Hua Shih K-WC, Yu C-C, Kao M-C, Chen MY, Wang T-H, Chih T-Y, Chen Y-L, Shie T-M. 2015. Hinokitiol suppressed pan-histone expression and cell growth in oral squamous cell carcinoma cells. *Journal of Functional Foods* 15:452–463 DOI 10.1016/j.jff.2015.03.036.

Yu Y, Yang J, Li Q, Xu B, Lian Y, Miao L. 2017. LINC00152: a pivotal oncogenic long non-coding RNA in human cancers. *Cell Proliferation* 50(4):e12349 DOI 10.1111/cpr.12349.

Zhang CZ, Cheng XQ, Li JY, Zhang P, Yi P, Xu X, Zhou XD. 2016. Saliva in the diagnosis of diseases. *International Journal of Oral Science* 8:133–137 DOI 10.1038/ijos.2016.38.